Printer Friendly

Fate Therapeutics partners with BD to develop, commercialise iPSC technology.

M2 PHARMA-October 14, 2010-Fate Therapeutics partners with BD to develop, commercialise iPSC technology(C)2010 M2 COMMUNICATIONS

14 October 2010 - US Fate Therapeutics Inc said today it has signed a collaboration and licence agreement with BD (Becton, Dickinson and Company) (NYSE: BDX), through its BD Biosciences segment, for the joint development and worldwide commercialisation of induced pluripotent stem cell (iPSC) tools and technologies for drug discovery and development.

Under the three-year collaboration, Fate and BD will endeavor to co-develop certain stem cell products using Fate's iPSC technology platform, and BD will commercialise these stem cell products on a worldwide basis.

Under the terms of the agreement, which includes exclusive licences to certain inventions of Dr Rudolf Jaenisch, founding member of the Whitehead Institute for Biomedical Research and scientific founder of Fate Therapeutics, and of Sheng Ding, associate professor at The Scripps Research Institute and scientific founder of Fate Therapeutics, Fate and BD will tap Fate's platform of industrialised pluripotent stem cell technology.

The collaboration includes a licence to US Patent No. 7,682,828 entitled "Methods for Reprogramming Somatic Cells," which is believed to be the earliest art that describes broad methods and key agents to reprogram human somatic cells to a pluripotent state.

Fate will receive an upfront payment, research funding, commercialisation milestones and royalties on the sale by BD of co-developed products.

Fate and BD said they expect that the products developed under the collaboration will serve as powerful tools for discovering new medical treatments and bridging the gap between the laboratory and the clinic.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 14, 2010
Words:268
Previous Article:GlaxoSmithKline to expand albendazole donations.
Next Article:Labopharm and Paladin sign licensing, distribution deals.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters